Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mayo Clinic | OTHER |
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tegaserod and Placebo | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the effect of one week of tegaserod on the passage of content through the gut by radiological procedures. |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the PD effects of tegaserod on upper & lower GI transit | ||
| To evaluate global well-being & upper and lower GI symptoms in daily assessment of bowel habits and weekly global and individual symptom assessments |
Not provided
Inclusion Criteria:
Females aged 18 to 64 years of age
Patients must present with two or more of the following criteria for chronic constipation for at least 12 weeks prior to entering the study:
Patients must report overlapping symptoms consistent with dyspepsia, such as mid-upper abdominal discomfort characterized by early satiety, post-meal fullness and bloating
Exclusion Criteria:
Patients with a recent history of, or current frequency of diarrhea occuring more than once per month off of laxatives
Clinically significant diagnosis of pelvic outlet obstruction or pelvic floor dyssenergia as determined by the study physicians
Patients with constipation secondary to medication use as determined by the study physician
Patients with clinically significant abnormal TSH levels at screening
Patients that have heartburn or abdominal pain as their predominant GI symptom
Evidence of cathartic colon or a history of laxative abuse
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicholas Talley, MD | Mayo Clinic | Principal Investigator |
| Michael Crowell, PhD | Mayo Clinic | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D003248 | Constipation |
| D004415 | Dyspepsia |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C105050 | tegaserod |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided